E3 PreliminaryPreliminaryPEM ?Peer-reviewedMachine draft
Clinical activity of folinic acid in patients with chronic fatigue syndrome.
Lundell, Kathleen, Qazi, Sanjive, Eddy, Linda et al. · Arzneimittel-Forschung · 2006 · DOI
Quick Summary
This study looked at 58 ME/CFS patients and found that most had weakened immune systems with low levels of a type of immune cell called B-lymphocytes, and most also had reactivated Epstein-Barr virus (EBV) infection. When researchers gave patients folinic acid (a form of vitamin B), about 81% reported feeling better. The findings suggest that folinic acid might help some ME/CFS patients and that immune problems may play a role in the illness.
Why It Matters
This study provides an early mechanistic link between immune dysfunction (B-cell depletion) and ME/CFS, and identifies folinic acid as a potentially accessible intervention with a high reported response rate. For patients, it offers a low-risk, low-cost option worth discussing with their healthcare provider; for researchers, it suggests immune profiling and B-cell function deserve further investigation as therapeutic targets.
Observed Findings
- 100% of the 58 CFS patients showed evidence of prior EBV exposure
- 72% had serological evidence of reactivated EBV infection
- 94% had B-cell immunodeficiency with marked CD19+IgM+ mature B-lymphocyte depletion
- 81% of patients reported subjective symptom improvement after folinic acid treatment
Inferred Conclusions
- B-cell immunodeficiency and inappropriate EBV antibody responses frequently accompany CFS
- CFS may represent a folinic acid-responsive clinical entity in a substantial proportion of patients
- Improper immune function, particularly in B-cell populations, may contribute to ME/CFS pathogenesis
Remaining Questions
- What is the mechanism by which folinic acid improves symptoms in CFS patients?
- Do the improvements persist long-term, and what is the optimal dosing regimen?
- How do B-cell defects relate mechanistically to symptom generation, and can their correction reverse symptoms?
- How would these findings replicate in a double-blind, placebo-controlled study with objective outcome measures?
What This Study Does Not Prove
This study does not prove that folinic acid cures or universally treats ME/CFS, as it lacks a placebo control group and relies on subjective patient reports rather than objective biomarkers of improvement. It does not establish that EBV reactivation or B-cell depletion directly causes ME/CFS, only that these conditions frequently occur together. The mechanism by which folinic acid might improve symptoms remains unexplained.
Tags
Symptom:PainFatigue
Biomarker:AutoantibodiesBlood Biomarker
Phenotype:Infection-Triggered
Method Flag:Weak Case DefinitionNo ControlsSmall SampleExploratory Only
Metadata
- DOI
- 10.1055/s-0031-1296741
- PMID
- 16889122
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026